Sign in Subscribe
Vaccines

AstraZeneca Pauses £200 Million Investment in Cambridge Research Site

Strategic Insights

— 2 min read

AstraZeneca, the UK's largest company, has paused its planned £200 million investment in its Cambridge research site, citing a challenging business environment. The decision means that none of the company's planned new funding, originally announced in March 2024, is currently proceeding. This comes after the company scrapped plans to invest £450 million in its vaccine manufacturing plant in northern England in January, due to reduced government support. The move is the latest in a string of withdrawals by pharmaceutical companies from the UK.

Key Takeaways:

  • AstraZeneca has paused its £200 million investment in its Cambridge research site, citing a challenging business environment.
  • The decision means that none of the company's planned new funding, originally announced in March 2024, is currently proceeding.
  • AstraZeneca has scrapped plans to invest £450 million in its vaccine manufacturing plant in northern England due to reduced government support.
  • The company's decision is the latest in a string of withdrawals by pharmaceutical companies from the UK.
  • Other companies, such as Merck & Co, have also announced plans to retreat from the UK due to its challenging business environment.
  • AstraZeneca's CEO, Pascal Soriot, has urged the British government to improve the environment for businesses in order to drive investment.
  • The Association of the British Pharmaceutical Industry (ABPI) has stated that Britain is "increasingly being ruled out of consideration as a viable location for pharmaceutical investment".
  • Talks between drugmakers and the government on how much revenue should be returned to Britain's health service have stalled.

Statistics:

  • £200 million: The planned investment in AstraZeneca's Cambridge research site that has been paused.
  • £450 million: The planned investment in AstraZeneca's vaccine manufacturing plant in northern England that was scrapped due to reduced government support.
  • By 2030: The target year for AstraZeneca's US manufacturing and research expansion, as part of its £50 billion investment plan.
  • 1,000 jobs: The number of jobs that the £200 million investment in Cambridge was expected to create.

Sources:

  • Britain's biggest company AstraZeneca has paused a planned 200 million pound ($271.26 million) investment in its Cambridge research site, a spokesperson said.
  • A U.S. drugmaker Merck & Co also said this week that it was abandoning a new research centre in London, citing the UK's challenging business environment.
  • In January, the company scrapped plans to invest 450 million pounds in its vaccine manufacturing plant in northern England, citing a cut in British government support.
  • AstraZeneca, which has the biggest market capitalisation on the FTSE 100, in July said it would spend $50 billion to expand its U.S. manufacturing and research by 2030.
  • The Association of the British Pharmaceutical Industry (ABPI) this week said Britain was "increasingly being ruled out of consideration as a viable location for pharmaceutical investment", as talks between drugmakers and the government on how much revenue should be returned to Britain's health service have stalled.

Read more